USE OF NIFUROXAZIDE IN THE FORM OF A COMPONENT OF A COMBINED DRUG THERAPY FOR TREATING DISEASES ASSOCIATED WITH HELICOBACTER PYLORI AND A CURING METHOD FOR ERADICATING A CAUSATIVE AGENT

The invention relates to medicine, in particular to gastroenterology and is directed at treating diseases associated with the infection generated by Helibacter pylori and at eradicating said causative agent. The invention consists in using nifuroxazide in the form of a component of a combined drug therapy of gastrointestinal tract diseases associated with the Helibacter pylori infection, wherein said combined drug therapy is directed at eradicating the causative agent and contains nifuroxazide, a component for controlling acid-forming processes in a stomach and at least one additional antibacterial component, which is effectiveagainst Helibacter pylori, or tripotassium bismuth dicitrate. The invention also relates to a method which is used for treating diseases associated with the infection generated by Helibacter pylori, directed at eradicating said causative agent and consists in administering the invective components for combined therapy in a therapeutically effective quantity. The inventive curative method makes it possible to efficiently eradicate the causative agent, is alternatively low-cost with respect to applied therapeutic regiments of first-order therapy and practically does not causes secondary effects. The preferred embodiment of nifuroxazide is Enterofuryl in the form of a peroral suspension. The inventive method is particularly useful for treating children. Ovaj pronalazak spada u oblast medicine, posebno gastroenterologye, usmeren je na lečenje obolenja indiciranih na infekciju izazvanu bakterijom Helicobacter pylori i na eradikaciju uzročnika. Ovaj pronalazak predviđa korištenje nifuroksazida kao komponente kombinovane terapije obolenja želudačno-crevnog trakta indiciranog na infekciju H. pylori, u kojoj je kombinovana terapija usmerena na eradikaciju uzročnika i uključuje: nifuroksazid, komponentu koja regulira procese stvaranja kiseline u želucu i najmanje jednu dopunsku anti-bakterijsku komponentu, efektivnu protiv H. pylori, i/ili bizmut trikalij dicitrata. Ovaj pronalazak, također, osigurava način lečenja obolenja indiciranih na infekciju izazvanu bakterijom H. pylori, usmerenu na eradikaciju uzročnika i koji predviđa uvođenje komponenti kombinovane terapije u količini terapeutski efektivnoj. Predloženi način lečenja obezbeđuje efektivnu eradikaciju uzročnika, on je alternativa jeftinija od šema terapije prve linije, koje se primenjuju i praktično ne izaziva neželjene efekte. Enterofuril u formi suspenzije za oralnu upotrebu je prepa